Where does Asthmatx, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Asthmatx, Inc. ranks #38,913 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Asthmatx, Inc. hold?

Asthmatx, Inc. holds 6 US utility patents granted between 2015 and 2016, spanning 4 technology areas.

What is Asthmatx, Inc.'s Innovation Score?

Asthmatx, Inc. has an Innovation Score of 26.5 out of 100 (20th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Asthmatx, Inc. focus on?

Asthmatx, Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 6 patents. Grants appear in 4 CPC subclasses total.

Is Asthmatx, Inc.'s patent grant rate increasing or decreasing?

Asthmatx, Inc.'s recent grant velocity is -100% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Asthmatx, Inc.'s patents?

Asthmatx, Inc.'s patents average 21.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Asthmatx, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Asthmatx, Inc.

USPTO PatentsView assignee record - 6 granted patents across 4 technology areas, recorded in grant years 2015–2016. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Asthmatx ranks #38,913 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 4 technology areas.

#38,913
of 49,997 US assignees by volume: 20th percentile
by Innovation Score (26.5/100): 21.2
avg claims per patent: -100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R38913 · US Corporation #38,913 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 6 grants
LOWER-Q #38,913/49,997
PHOTO-FINISH Asian Express Holdings
CPC-NARROW A61B · 4 areas
INNOV-THIN 26.5/100
CLAIMS-DENSE 21.2 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Asian Express Holdings Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Asthmatx · this assignee

26
3D Lighting… · lowest

7

What this shows Asthmatx's Innovation Score is 26.5/100 (20th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Asthmatx's grants concentrate

Asthmatx, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2015 (5 grants) versus a trough of 1 in 2016. By volume, Asthmatx sits between Asian Express Holdings Limited and Atlantis Computing, Inc..

Asian Express Hol…

6
Asoka USA

6
Aspects

6
Assembled Products

6
Astrazeneca Compu…

6
Astral Images

6
Athentek Innovati…

6
Atlantis Computing

6
Asthmatx ◀

6

What this shows Asthmatx holds 6 patents at rank #38,956, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Asthmatx

By rank, the assignees closest to #38,956 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Asthmatx's primary technology class.

Asthmatx's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

26 20th percentile higher than 20% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2016

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Asthmatx, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	5	83.3%
2016	1	16.7%

Which technologies does Asthmatx, Inc. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 6

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 6

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 3

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 2

Top 4 of 4 technology areas

Where it ranks

Overall rank by patents

#38,913

of 49,997 tracked assignees

Innovation Score

26.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Asthmatx, Inc.'s patent record in context - here's where to go next.

Asthmatx, Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 100% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #38,913 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Asthmatx, Inc. against Asian Express Holdings Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 26.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.